PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Golimumab - Non-radiographic axial spondyloarthritis
PAD Profile : Golimumab - Non-radiographic axial spondyloarthritis
Keywords :
Biologic, anti-TNF, TNF-alpha, monoclonal antibody, cytokine modulator, nrAS, nr-AS
Brand Names Include :
Simponi
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
- Ankylosing spondylitis
- Any paediatric use
- Psoriatic arthritis
- Rheumatoid arthritis
- Inflammatory bowel disease
Additional Documents
Type
Document
Review Date
NICE Technology Appraisal
Committee Recommendations
Date
Committee Name
Narrative
06 December 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated axial spondyloarthritis pathway.
Treatment pathway is available on separate guidelines page.
26 March 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Prescribing Clinical Network recommends Golimumab as a treatment option for non-radiographic axial spondyloarthritis in line with NICE TA497 (January 2018).
Golimumab for this indication will be considered as RED on the traffic light status (treatment should be initiated and continued by specialist clinicians)
Golimumab is a payment by results excluded drug and specialists will be required to notify commissioners of initiation and response to treatment using the tick box proformas available on the blueteq system.
Associated BNF Codes
10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs